Advertisement

Advertisement

2022 ASCO Annual Meeting

prostate cancer

Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel ...

prostate cancer

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET ...

bladder cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity w...

breast cancer

Richard Finn, MD, on Advanced Breast Cancer: New Data on Palbociclib Plus Letrozole From PALOMA-2

Richard Finn, MD, of the Geffen School of Medicine at UCLA and the Jonsson Comprehensive Cancer Center, discusses analyses from the PALOMA-2 trial on overall survival with first-line palbociclib plus ...

gynecologic cancers
immunotherapy

Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion...

Neuroendocrine Tumors

Capecitabine Plus Temozolomide for Advanced Pancreatic Neuroendocrine Tumors

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors, but researchers found that patients treated with a combination of capecitabine and temozolomide had...

Leukemia

FLT3 Inhibitor Crenolanib in Combination With Chemotherapy for Newly Diagnosed Patients With FLT3-Mutant AML

Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, and colleagues presented the long-term results of a phase II clinical trial combining crenolanib, a second-generation FL...

Symptom Management

Weekly Electronic Reporting of Symptoms Improved Outcomes in Patients With Advanced Cancer

People with advanced cancer who communicated their symptoms weekly using an electronic survey had about one-third better physical function and over a 15% better control of their symptoms compared to t...

Lung Cancer
Immunotherapy

Ramucirumab/Pembrolizumab vs Standard of Care in Patients With Advanced NSCLC Previously Treated With Immune Checkpoint Inhibitors

In the phase II Lung-MAP substudy S1800A presented at the 2022 ASCO Annual Meeting (Abstract 9004) and simultaneously reported in the Journal of Clinical Oncology, Karen L. Reckamp, MD, and colleagues...

Gynecologic Cancers

ATHENA-MONO Trial: Rucaparib Maintenance in Newly Diagnosed Patients With Advanced Ovarian Cancer

As presented at the 2022 ASCO Annual Meeting (Abstract LBA5500) and simultaneously reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III ATHENA-MONO trial ...

Genomics/Genetics

Patient-Facing Screening Tool Could Increase Detection of Individuals With Lynch Syndrome

Nearly 1 million people in the United States are affected by Lynch syndrome, a hereditary cancer condition with markedly elevated risk of gastrointestinal, endometrial, and other cancers. Most of them...

CNS Cancers
Immunotherapy

Immunotherapy Combination in Newly Diagnosed Glioblastoma

A novel combination of two experimental cancer immunotherapy agents along with an immune checkpoint blocker elicited robust immune responses in patients with newly diagnosed glioblastoma brain tumors,...

Pancreatic Cancer
Immunotherapy

Three-Arm First-Line Chemoimmunotherapy Study in Patients With Metastatic Pancreatic Cancer

Combinations of chemotherapy and immunotherapy showed activity in patients with metastatic pancreatic cancer, according to findings from a national, randomized clinical trial led and sponsored by the ...

Breast Cancer
Genomics/Genetics

Study Finds Genetic Mutations Differ Across Younger and Older Patients With Breast Cancer

Women younger than age 40 with advanced breast cancer often experience more aggressive disease and worse prognoses than their older counterparts. Knowing which types of genetic mutations these patient...

Health-Care Policy
Legislation

Did the ACA’S Medicaid Expansion Affect Cancer Clinical Trial Enrollment?

Researchers from the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), found that the Affordable Care Act’s (ACA) expansion of Medicaid insurance in ...

Breast Cancer

Biomarker Guidance May Allow Patients Aged 55 or Older With Low-Grade Luminal A–Type Breast Cancer to Avoid Radiation Therapy

Based on guidance from biomarker screening, patients with low-grade luminal A–type breast cancer aged 55 and older may need endocrine therapy alone following breast-conserving surgery and may be able ...

skin cancer
immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Distant Metastasis–Free Survival With Adjuvant Pembrolizumab

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses phase III findings from the KEYNOTE-716 study. The trial showed that compared with placebo, adjuvant...

pancreatic cancer

Alfredo Carrato, MD, PhD, on Pancreatic Cancer: Nab-Paclitaxel, Gemcitabine, and FOLFOX for Metastatic Disease

Alfredo Carrato, MD, PhD, of Alcala de Henares University in Spain, discusses phase II results from the SEQUENCE trial, which showed that nab-paclitaxel, gemcitabine, and modified FOLFOX showed signif...

neuroendocrine tumors

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progr...

breast cancer

Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib

Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus c...

skin cancer

Georgina V. Long, MD, PhD, on Melanoma: New Data on Pembrolizumab, Dabrafenib, and Trametinib

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses findings from the NeoTrio trial on neoadjuvant pembrolizumab alone, in sequence with, or concurrent ...

bladder cancer

Shilpa Gupta, MD, on Urothelial Cancer: Defining Who Is 'Platinum-Ineligible'

Shilpa Gupta, MD, of the Cleveland Clinic Foundation, discusses an updated consensus definition for standard therapy and clinical trial eligibility for patients with metastatic urothelial cancer who a...

leukemia

Courtney D. DiNardo, MD, MSCE, and Stéphane de Botton, MD, PhD, on AML: New Data on IDH2-Mutant Alleles, Enasidenib, and Conventional Care

Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Stéphane de Botton, MD, PhD, of Institut Gustave Roussy, discuss phase III findings from the IDHENTIFY trial, w...

head and neck cancer
supportive care

Carryn M. Anderson, MD, on Head and Neck Cancer: New Data on Avasopasem Manganese for Oral Mucositis

Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses phase III results of the ROMAN trial of avasopasem manganese for patients with severe oral mucositis who are receiving chemoradiot...

lymphoma
immunotherapy

Stephen M. Ansell, PhD, MD, on Hodgkin Lymphoma: An Updated Analysis on First-Line Brentuximab Vedotin Plus Chemotherapy

Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combi...

gynecologic cancers

Ursula A. Matulonis, MD, and Nicoletta Colombo, MD, on Ovarian Cancer: Overall Survival Data on Relacorilant Plus Nab-Paclitaxel

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival...

Sarcoma
Immunotherapy

Neoadjuvant Immunotherapy May Improve Survival for Patients With Soft-Tissue Sarcoma

In a phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiate...

Kidney Cancer

Researchers Examine Racial Differences in Treatment and Outcomes of First-Line Therapies for Kidney Cancer

Black and White patients treated with similar first-line therapies for advanced kidney cancer experienced similar outcomes, but different response rates, according to research from Fox Chase Cancer Ce...

Colorectal Cancer
Immunotherapy

'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly

Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients w...

leukemia

Courtney D. DiNardo, MD, MSCE, and Jorge E. Cortes, MD, on CML: New Efficacy and Safety Results for Asciminib

Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discuss phase III results from the ASCEMBL...

breast cancer

Lisa A. Carey, MD, and Hope S. Rugo, MD, on Advanced Breast Cancer: New Data on Sacituzumab Govitecan-hziy vs Treatment of Physician’s Choice

Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, Helen Diller Family Comprehensive C...

CNS Cancers

Dabrafenib Plus Trametinib Improve Overall Response Rates vs Standard-of-Care Chemotherapy in Pediatric Patients With Low-Grade Gliomas

The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemothera...

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial...

gynecologic cancers

Benoit You, MD, PhD, on Ovarian Cancer: Who Benefits From Bevacizumab in the First-Line Setting

Benoit You, MD, PhD, of Lyon University hospital (HCL, France) and GINECO group (France), discusses findings from the GOG-0218 trial of patients with ovarian cancer, which appears to confirm earlier d...

breast cancer

Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for ...

supportive care
symptom management

Sriram Yennu, MD, on Cancer-Related Fatigue: Is Open-Labeled Placebo an Effective Treatment?

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses the placebo response in patients with advanced cancer and cancer-related fatigue. His latest findings show that open-l...

bladder cancer

Karim Chamie, MD, on Bladder Cancer: Final Results on N-803 and Bacillus Calmette-Guérin

Karim Chamie, MD, of the University of California, Los Angeles, discusses final clinical results on combining the superagonist N-803 with bacillus Calmette-Guérin (BCG) in patients whose carcinoma in ...

multiple myeloma

Paul G. Richardson, MD, on Multiple Myeloma: New Data on Lenalidomide, Bortezomib, and Dexamethasone, With or Without ASCT

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III findings from the DETERMINATION trial, which showed that, for patients with newly diagnosed multiple myeloma, lenalidomide,...

Brentuximab Vedotin Plus Chemotherapy vs Chemotherapy Alone for Pediatric Patients With Hodgkin Lymphoma

A new study has shown that a combination of brentuximab vedotin and standard chemotherapy is safe and appears to be more effective than standard chemotherapy in pediatric patients up to age 21 with ne...

Racial/Ethnic Disparities and Cardiovascular Mortality Among Cancer Survivors

A recent large national study showed the mortality risk from cardiovascular disease differs considerably among cancer survivors by race/ethnicity and cancer types. The findings are being presented by ...

Breast Cancer

Study Offers Guidance for Future Trials of Adjuvant Therapy for Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer

To fully evaluate hormone-blocking therapy following surgery for patients with early-stage high-risk hormone receptor–positive/HER2-negative breast cancer, researchers should continue to track patient...

Multiple Myeloma

Including ASCT as Part of Initial Therapy Improves Progression-Free Survival in Newly Diagnosed Patients With Multiple Myeloma

The use of autologous stem cell transplantation (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed patients w...

Sarcoma

Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas

Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according ...

Breast Cancer

Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer

The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy. It also significantly improved overall surviv...

Colorectal Cancer

Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer

The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who re...

myelodysplastic syndromes

Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol

Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients w...

pancreatic cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates wit...

Breast Cancer

Endocrine Sensitivity Test Predicts Survival Benefit of Dose-Dense Chemotherapy for Patients With Hormone Receptor–Positive Breast Cancer

A new genomic test designed to measure the endocrine sensitivity of estrogen receptor–positive breast cancer has the potential to identify patients diagnosed with the disease who could benefit more fr...

Colorectal Cancer
Issues in Oncology

Study Reveals Racial Disparities in Guideline-Concordant Care for Patients With Early-Onset Colorectal Cancer

In a large national study, Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their White counterparts. Differences in health insurance coverage type,...

COVID-19

New Report Shows COVID-19 Pandemic Increased Cancer-Related Deaths in the United States

According to a new study led by researchers at the American Cancer Society, the COVID-19 pandemic increased the number of cancer-related deaths by 3.2% in the United States from 2019 to 2020. Compared...

Advertisement

Advertisement



Advertisement